AZD5672 Bioavailability Study in Healthy Male and Female Subjects
Study identifier:D1710C00019
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An Open-label, Randomized, 4 Period Crossover, Replicate Study to Assess the Relative Bioavailability of the Phase III and Phase IIb Formulations of AZD5672 in Healthy Male and Female Subjects
Medical condition
Rheumatoid Arthritis
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD5672
Sex
All
Actual Enrollment
24
Study type
Interventional
Age
18 Years - 55 Years
Date
Study Start Date: 01 Mar 2009
Primary Completion Date: -
Study Completion Date: 01 May 2009
Study design
Allocation: Randomized
Endpoint Classification: Bio-availability Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Other
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 40 or 100mg AZD5672, Reference formulation | Drug: AZD5672 40 mg tablet (Reference formulation) Drug: AZD5672 100 mg (2 x 50 mg tablet (Reference Formulation) |
| Experimental: 2 40 or 100mg AZD5672, Test formulation | Drug: AZD5672 40 mg tablet (Test formulation) Drug: AZD5672 100 mg tablet (Test formulation) |
Contacts
Investigators
Principal Investigator
Mark Layton
AstraZeneca R&D, Alderley Park, UK
